Press releases

23 May 2024

UCB announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa

17 May 2024

Transparency notification Wellington

17 May 2024

Acquisition of own shares

14 May 2024

New data published in the Journal of Neurology show clinically meaningful improvement of fatigue in generalized myasthenia gravis (gMG) with ZILBRYSQ[®]▼ (zilucoplan)

10 May 2024

Acquisition of own shares

8 May 2024

UCB presents final open-label extension FINTEPLA®▼(fenfluramine)[1] data at International Child Neurology Congress (ICNC) Annual Meeting

Press releases

Press releases

Search Press releases

UCB announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa

Transparency notification Wellington

Acquisition of own shares

New data published in the Journal of Neurology show clinically meaningful improvement of fatigue in generalized myasthenia gravis (gMG) with ZILBRYSQ[®]▼ (zilucoplan)

Acquisition of own shares

UCB presents final open-label extension FINTEPLA®▼(fenfluramine)[1] data at International Child Neurology Congress (ICNC) Annual Meeting

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa

Transparency notification Wellington

Acquisition of own shares

New data published in the Journal of Neurology show clinically meaningful improvement of fatigue in generalized myasthenia gravis (gMG) with ZILBRYSQ[®]▼ (zilucoplan)

Acquisition of own shares

UCB presents final open-label extension FINTEPLA®▼(fenfluramine)[1] data at International Child Neurology Congress (ICNC) Annual Meeting

Choose a Country